NCT00913835 2019-09-26A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian CancerEli Lilly and CompanyPhase 2 Completed125 enrolled 20 charts